Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

AstraZeneca agrees to buy ZS Pharma for $2.7 billion

Published 11/06/2015, 02:21 AM
Updated 11/06/2015, 02:30 AM
AstraZeneca agrees to buy ZS Pharma for $2.7 billion
AZN
-
ZSPH
-

LONDON (Reuters) - Britain's AstraZeneca Plc (L:AZN) said on Friday it had agreed to buy ZS Pharma (O:ZSPH), paying a total $2.7 billion for its proprietary technology to develop novel treatments for hyperkalaemia, or high potassium levels.

AstraZeneca said it had agreed to pay $90 a share for the San Mateo, California-based firm.

Hyperkalaemia is typically associated with chronic kidney disease and chronic heart failure, AstraZeneca said, adding that peak sales of the company's ZS-9 potassium-binding compound, which is under review by the FDA, were forecast to exceed $1 billion.

The transaction does not impact AstraZeneca's financial guidance for 2015. It is expected to generate Product Sales from 2016, with minimal earnings dilution over 2016 and 2017, becoming accretive to AstraZeneca's core earnings from 2018.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.